Sertindole (Serdolect): Preclinical and clinical findings of a new atypical antipsychotic

J. M. Kane, C. A. Tamminga

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


This review first describes the preclinical findings with sertindole, a novel phenyl indole derivative antipsychotic agent. Secondly, a summary is provided of the major clinical trials conducted to date. Based on these findings, sertindole appears to be an effective antipsychotic agent for the treatment of positive and negative symptoms of schizophrenia, with efficacy that is clearly superior to placebo. Sertindole is as effective as haloperidol, but is much better tolerated with significantly fewer adverse neurological effects across a wide dosage range of both drugs. Sertindole is associated with a significant mean prolongation of the QT and QT(c) intervals of 3 - 6% from baseline in placebo-controlled studies. This potential adverse effect should be taken into account when treating specific patients with known risk factors for ventricular arrhythmias. Sertindole should prove to be a very useful addition to the therapeutic options available for the treatment of psychotic disorders.

Original languageEnglish (US)
Pages (from-to)1729-1741
Number of pages13
JournalExpert Opinion on Investigational Drugs
Issue number11
StatePublished - 1997

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Sertindole (Serdolect): Preclinical and clinical findings of a new atypical antipsychotic'. Together they form a unique fingerprint.

Cite this